On this page
1q21.1 duplication syndrome
This condition arises from a duplication (extra copy) of DNA in the 1q21.1 region of chromosome 1. The clinical features vary considerably between individuals, ranging from no obvious effects to developmental delay, distinctive facial features, and growth differences. Many affected individuals are identified through testing performed for developmental concerns or during family studies.
Overview
1q21.1 duplication syndrome results from having an additional copy of genetic material in the 1q21.1 region of chromosome 1. This means affected individuals have three copies of this particular chromosomal segment rather than the usual two. The size of the duplication can vary, which contributes to the wide range of features observed.
The condition was first clearly characterised following advances in chromosomal microarray technology, which can detect small copy number changes not visible on standard chromosome analysis. Research suggests the duplication occurs in approximately 1 in 4,000 to 1 in 10,000 individuals, though exact prevalence remains uncertain because some people with the duplication never develop noticeable symptoms. The condition affects males and females equally.
Because the clinical features are highly variable and can be mild, many individuals with 1q21.1 duplication are never diagnosed. Some are identified only when genetic testing is performed for developmental concerns, autism spectrum features, or when a family member is diagnosed and relatives are subsequently tested.
Symptoms & clinical features
The clinical features of 1q21.1 duplication syndrome vary markedly between affected individuals. Some people with the duplication show no obvious symptoms, whilst others experience developmental and physical differences. Common features include mild to moderate developmental delay, particularly affecting speech and language acquisition. Learning difficulties occur in some individuals, though many attend mainstream education with appropriate support.
Physical features may include distinctive facial characteristics, though these are often subtle and not always present. Some affected individuals are taller than average or have larger head size (macrocephaly). Behavioural differences are noted in some people, including features associated with autism spectrum conditions or attention difficulties. A small proportion of individuals with the duplication may experience seizures. Heart defects and other organ involvement occur less commonly. The presence and severity of features cannot be reliably predicted from the size of the duplication alone, and identical duplications can produce different outcomes even within the same family.
Video: Genetics 101
Affected organs
The 1q21.1 duplication primarily affects the developing nervous system, which explains why developmental delay, learning differences, and behavioural features are the most commonly reported manifestations. Brain imaging studies in some affected individuals have revealed structural variations, though these findings are not universal.
Growth patterns may be affected, with some individuals showing increased height or head circumference compared to family expectations. The heart is involved in a minority of cases, with congenital heart defects reported in some individuals. Other body systems are generally less affected, though skeletal differences and joint laxity have been noted occasionally. The spectrum of involvement reflects the fact that the duplicated region contains multiple genes, each potentially contributing to different aspects of development.
Risks & severity
The severity of 1q21.1 duplication syndrome ranges from essentially undetectable to moderate developmental impact. Many individuals function well with appropriate educational support and lead independent lives. The condition is not typically associated with shortened lifespan, though this depends partly on whether significant heart defects or other medical complications are present.
Developmental outcomes vary widely. Whilst some individuals experience noticeable delays in reaching developmental milestones and require ongoing learning support, others attend mainstream education and achieve age-appropriate skills. Speech and language development is often the area most affected. The risk of autism spectrum features appears higher than in the general population, though most people with the duplication do not meet diagnostic criteria for autism. Seizures, when they occur, typically respond to standard treatments. The presence of the duplication in an unaffected parent demonstrates that penetrance is incomplete - not everyone with the genetic change develops clinical features.
Genetic causes
1q21.1 duplication syndrome is caused by having an extra copy of DNA in the 1q21.1 chromosomal region. This region contains several genes, and having three copies instead of the usual two disrupts normal gene dosage. The duplication typically arises through errors in chromosomal recombination, often occurring at regions of repetitive DNA sequence that flank the 1q21.1 area.
The duplicated segment usually encompasses multiple genes whose products are involved in various developmental processes. The variable clinical picture likely reflects which specific genes are included in the duplication, the size of the duplicated segment, and individual genetic background factors that modify the effect. The duplication can be detected using chromosomal microarray analysis, which has become standard in investigating unexplained developmental delay. Standard chromosome analysis (karyotyping) typically cannot detect duplications of this size.
Inheritance pattern
Most cases of 1q21.1 duplication occur as new (de novo) events, meaning the duplication arose in the egg or sperm that formed the affected individual, and neither parent carries it. However, inherited cases do occur - when a parent carries the duplication, each of their children has a 50% chance of inheriting it. This is because the duplication is located on one of the two copies of chromosome 1, and each child randomly inherits one or the other.
Importantly, inheriting the duplication does not guarantee symptoms will develop. The condition shows incomplete penetrance and variable expressivity, meaning some people with the duplication are unaffected whilst others show features, and the severity varies even among relatives with the same duplication. When a child is diagnosed, parental chromosomal microarray testing is typically offered to determine whether the duplication was inherited or occurred de novo, as this information affects recurrence risk for future pregnancies.
Diagnosis & testing
Diagnosis of 1q21.1 duplication syndrome is confirmed through chromosomal microarray analysis (also called array comparative genomic hybridisation or array CGH), which can detect the extra copy of the 1q21.1 region. This test is often performed as part of investigations for unexplained developmental delay, learning difficulties, autism spectrum features, or congenital anomalies.
In the UK, chromosomal microarray testing is available through the NHS Genomic Medicine Service for individuals meeting specific clinical criteria. Referral is typically made by a paediatrician, clinical geneticist, or other specialist. Genetic counselling is an important part of the diagnostic process, helping families understand the implications of testing and interpreting results. When a duplication is identified in a child, testing may be offered to parents and sometimes other family members to clarify inheritance pattern and inform reproductive planning.
Management & lifestyle
Management of 1q21.1 duplication syndrome is tailored to each individual's specific needs and focuses on supporting development and addressing any medical complications. There is no specific treatment for the underlying chromosomal change itself. Children with developmental delay benefit from early intervention services, including speech and language therapy, occupational therapy, and educational support adapted to their learning profile.
If autism spectrum features or attention difficulties are present, appropriate behavioural and educational strategies are implemented, following standard NHS care pathways for these conditions. Regular developmental monitoring helps identify emerging needs. When seizures occur, standard antiepileptic management is employed. Heart defects, if present, are managed according to their specific nature and severity, typically through paediatric cardiology services. Growth monitoring is appropriate given the tendency toward increased height and head size in some individuals. Families benefit from ongoing contact with clinical genetics services and access to genetic counsellors who can provide information about recurrence risks and testing options for family planning.
UK care pathway
In the UK, individuals with suspected 1q21.1 duplication syndrome are typically referred to clinical genetics services through their GP, paediatrician, or specialist. The NHS Genomic Medicine Service provides access to chromosomal microarray testing for eligible patients, particularly those with unexplained developmental delay, learning disability, or autism spectrum features in combination with other clinical findings.
Genetic counselling is available through NHS clinical genetics departments and helps families understand test results, inheritance patterns, and implications for other family members. Following diagnosis, ongoing care is coordinated through paediatric or adult services as appropriate, with input from relevant specialists depending on individual needs. Support organisations can provide valuable peer support and information for families navigating the condition.
Frequently asked questions
Will my child with 1q21.1 duplication syndrome be able to attend mainstream school?
Many children with this duplication attend mainstream schools, often with additional learning support tailored to their needs. Educational outcomes vary considerably - some children require minimal support whilst others benefit from specialist educational provisions. Developmental assessments help determine the most appropriate educational setting for each individual child.
If I have the duplication but no symptoms, will my children definitely be affected?
No. If you carry the duplication, each child has a 50% chance of inheriting it, but inheriting the duplication does not guarantee symptoms will develop. Some people with the duplication show no obvious features whilst others experience developmental differences, even within the same family.
Can 1q21.1 duplication syndrome be detected during pregnancy?
Yes, chromosomal microarray analysis can be performed on samples obtained through amniocentesis or chorionic villus sampling during pregnancy. This testing would typically be considered if the duplication is already known to run in the family or if pregnancy ultrasound shows features prompting further investigation. Genetic counselling before testing helps families consider the implications.
Why do some people with 1q21.1 duplication have no symptoms?
The reasons for incomplete penetrance are not fully understood but likely involve interactions with other genes and environmental factors that modify the effect of the duplication. This variable expressivity is characteristic of many chromosomal copy number variants and makes it difficult to predict outcomes for individual carriers.
References
- Wang F, Peng H, Lou G. Prenatal ultrasound phenotype of fetuses with recurrent 1q21.1 deletion and duplication syndrome. Frontiers in pediatrics. 2024. PMID: 39840309
- Gourari I, Schubert R, Prasad A. 1q21.1 Duplication syndrome and epilepsy: Case report and review. Neurology. Genetics. 2018. PMID: 29379884
- Minelli M, Palka Bayard de Volo C, Alfonsi M. 1q21.1 Duplication Syndrome and Anorectal Malformations: A Literature Review and a New Case. Current issues in molecular biology. 2025. PMID: 39852141
- Pang H, Yu X, Kim YM. Disorders Associated With Diverse, Recurrent Deletions and Duplications at 1q21.1. Frontiers in genetics. 2020. PMID: 32655619
- Ji X, Pan Q, Wang Y. Prenatal Diagnosis of Recurrent Distal 1q21.1 Duplication in Three Fetuses With Ultrasound Anomalies. Frontiers in genetics. 2018. PMID: 30177949
- Xavier J, Zhou B, Bilan F. 1q21.1 microduplication: large verbal-nonverbal performance discrepancy and ddPCR assays of HYDIN/HYDIN2 copy number. NPJ genomic medicine. 2018. PMID: 30155272
- Benítez-Burraco A, Barcos-Martínez M, Espejo-Portero I. Narrowing the Genetic Causes of Language Dysfunction in the 1q21.1 Microduplication Syndrome. Frontiers in pediatrics. 2018. PMID: 29922639
- Zhang H, Yue F, Zhang X. Prenatal detection of distal 1q21.1q21.2 microduplication with abnormal ultrasound findings: Two cases report and literature review. Medicine. 2021. PMID: 33429818